TerminatedNCT01939548

An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia

Medication studyAges 18–65United States

The study in practice

Understand this study

Listed age limits: 18 years to 65 years.

Listed locations: Birmingham and 43 more locationsSee all locations and recruitment
Study phase: Phase 2

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Study start dateOctober 2013

Recruitment status: Terminated
Enrollment listed in the registry: 240
Sponsor: Pfizer
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 2
Locations: United States
Age range: From 18 Years to 65 Years
Official registry ID: NCT01939548
Official title: Show the full official title
A 12-week , Randomized, Phase 2, Double-blind, Parallel-group Study Of Two Dose Levels Of Pf-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-optimally Controlled Symptoms Of Schizophrenia

Terminated

Birmingham · Little Rock · Cerritos

35 more locations

A listed location does not confirm current availability.

FAQ

Who is behind this study?

The study sponsor is Pfizer.

Does this study involve medication?

Yes. The study involves medication, including PF-02545920 and Placebo.

Who can participate?

Listed age limits: 18 years to 65 years.

Is this study still recruiting?

The registry lists this study as terminated.